Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Working to Uncover the Mode of Action

Posted on March 2nd, 2017 by in Pharma R&D

The hive

The New Year has brought some new talent into the Myelo Therapeutics team. In January we welcomed Susann, our new postdoctoral researcher. We’re excited to have someone with her experience, which includes studying molecular biology in Dresden and Heidelberg, and a master thesis in the area of hematopoietic stem cell research at the German Cancer Research Center. She went on to pursue her PhD in the lab of Prof. Claudia Waskow in Dresden, where she worked on humanized mouse models and gained extensive knowledge on human and murine hematopoiesis.

With this expertise, she will support us working at the intersection of academic research and industrial development to help further elucidate the mode of action of Myelo001, our orally applied, small molecule that displayed a chemo-protective effect, specific to healthy tissue. For her, this provides an opportunity to apply her expertise to a clinically relevant question and to gain an insight into the workings of pharma R&D.

Elsevier’s solutions have proven to be a great help in our work so far, and we are actively using ScienceDirect, PharmaPendium, Embase and Scopus. Myelo works with academic and for-profit research partners to conduct further molecular research on Myelo001. Scopus’s author search has been especially useful for identifying potential collaboration partners by offering in-depth analysis of publication frequency, relevancy and more. Therefore, Scopus saved us a lot of time in finding the right research partners, such as Professor Claudia Waskow at the Institute for Immunology of the TU Dresden.

Follow The Hive


 

All opinions shared in this post are the author’s own.

R&D Solutions for Pharma & Life Sciences

We're happy to discuss your needs and show you how Elsevier's Solution can help.

Contact Sales